Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.
Previously, we found that 4 weeks of treatment with lopinavir-ritonavir did not decrease insulin sensitivity but did increase adiponectin levels. In the present study, a single dose of lopinavir-ritonavir decreases insulin sensitivity but does not alter adiponectin levels. Insulin resistance from protease inhibitors may decrease with prolonged use; an increase in adiponectin levels may mediate this effect.
Lee
Grace A
GA
Department of Medicine, University of California, San Francisco, California, USA. galee@itsa.ucsf.edu
Lo
Joan C
JC
Aweeka
Francesca
F
Schwarz
Jean-Marc
JM
Mulligan
Kathleen
K
Schambelan
Morris
M
Grunfeld
Carl
C
D052242:Adiponectin / Q000097:blood / Q000378:metabolism; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000009:adverse effects; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects
D052242:Adiponectin; D019380:Anti-HIV Agents; D001786:Blood Glucose; D007328:Insulin; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir